[1] Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7):1849-2014.
[2] 邵幼林,范建高.非酒精性脂肪性肝病的流行现状与危害.中华肝脏病杂志,2019,27(1):10-13.
[3] Li J, Zou B, Yeo YH, et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
[4] Chalmers J, Wilkes E, Harris R, et al. Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Frontline Gastroenterol, 2020,11:86-92.
[5] Srivastava A, Jong S, Gola A, et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol,2019,19(1):122.
[6] 李勇,张诗雯,苏杭,等.我国分级诊疗试点现状及制约因素分析.中国药物评价,2019,36(6):406-410.
[7] 苏淑婷, 钟燕, 宓余强.非酒精性脂肪性肝病分级分期管理研究进展. 实用肝脏病杂志, 2019, 22(02):147-150.
[8] 王志翊,王仲,翁杰,等.医联体全科团队对居民家庭医生签约意愿的影响研究.中国全科医学,2018,21(27):3389-3392.
[9] Moolla A, Motohashi K, Marjot T, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol,2019,10(4):337-346.
[10] Puri P, Fuchs M. Populationmanagement of nonalcoholic fatty liver disease. Fed Pract,2019,36(2):72-82.
[11] 曾雁冰,王秋鹏,方亚.厦门市糖尿病“三师共管”模式的卫生经济学评价.山东大学学报(医学版),2019,57(8):89-94+109.
[12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[13] 李静,张梅,庄丽燕,等.社区体检人群脂肪肝流行情况及其危险因素分析.健康教育与健康促进,2019,14(06):537-540.
[14] 向润,李强.肺癌“一体化诊疗、全程管理”模式的发展现状与思考——基于四川省肿瘤医院肺癌MDT团队经验. 中国肺癌杂志,2020,23(4):211-215. |
